Voyager Therapeutics (VYGR) Tops Q4 EPS by 5c

Voyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of ($0.46), $0.05 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $15.34 million versus the consensus estimate of $9.19 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
• Citi raises Atlassian price target to $225, maintains Buy rating
• JPMorgan Downgrades Li Ning Co. Ltd. (2331:HK) (LNNGF) to Neutral